We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Oncology

Journal Scan / Research · November 01, 2018

Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Stage III Melanoma

Journal of Clinical Oncology

 

Additional Info

Journal of Clinical Oncology
Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma
J. Clin. Oncol 2018 Oct 22;[EPub Ahead of Print], A Hauschild, R Dummer, D Schadendorf, M Santinami, V Atkinson, M Mandalà, V Chiarion-Sileni, J Larkin, M Nyakas, C Dutriaux, A Haydon, C Robert, L Mortier, J Schachter, T Lesimple, R Plummer, K Dasgupta, T Haas, M Shilkrut, E Gasal, R Kefford, JM Kirkwood, GV Long

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading